NASDAQ:ALLR - Nasdaq - US0167445008 - Common Stock - Currency: USD
0.8461
+0.05 (+5.84%)
The current stock price of ALLR is 0.8461 USD. In the past month the price decreased by -20.93%. In the past year, price decreased by -94.37%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 18.48 | 335.32B | ||
AMGN | AMGEN INC | 13.99 | 156.11B | ||
GILD | GILEAD SCIENCES INC | 14.53 | 139.89B | ||
VRTX | VERTEX PHARMACEUTICALS INC | N/A | 115.69B | ||
REGN | REGENERON PHARMACEUTICALS | 11.13 | 53.25B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 39.23B | ||
ARGX | ARGENX SE - ADR | 101.9 | 35.78B | ||
ONC | BEONE MEDICINES LTD-ADR | 6.55 | 27.68B | ||
BNTX | BIONTECH SE-ADR | N/A | 26.08B | ||
NTRA | NATERA INC | N/A | 22.36B | ||
BIIB | BIOGEN INC | 8.42 | 19.51B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 15.29B |
Allarity Therapeutics, Inc. engages in the development of drugs for personalized treatment of cancer guided by its proprietary Drug Response Predictor (DRP) technology. The company is headquartered in Boston, Massachusetts and currently employs 6 full-time employees. The company went IPO on 2021-12-21. The company is focused on development of stenoparib, a PARP/tankyrase inhibitor for advanced ovarian cancer patients, using its DRP technology to develop a companion diagnostic that can be used to select those patients expected to derive clinical benefit from stenoparib. Its therapeutic candidate, stenoparib, is a dual inhibitor of the key DNA damage repair enzyme PARP, as well as Tankyrases, critical enzymes involved in the WNT signaling pathway commonly activated in many cancers. Inhibition of key DNA damage repair enzymes, such as PARP, has clinically demonstrated to be therapeutically beneficial in the treatment of cancers (ovarian cancers). The DRP method builds on the comparison of sensitive vs. resistant human cancer cell lines, including transcriptomic information from cell lines, combined with clinical tumor biology filters and prior clinical trial outcomes.
ALLARITY THERAPEUTICS INC
24 School St., 2Nd Floor
Boston MASSACHUSETTS US
Employees: 6
Phone: 14014264664
The current stock price of ALLR is 0.8461 USD. The price increased by 5.84% in the last trading session.
The exchange symbol of ALLARITY THERAPEUTICS INC is ALLR and it is listed on the Nasdaq exchange.
ALLR stock is listed on the Nasdaq exchange.
ALLARITY THERAPEUTICS INC (ALLR) has a market capitalization of 12.76M USD. This makes ALLR a Nano Cap stock.
ALLARITY THERAPEUTICS INC (ALLR) currently has 6 employees.
ALLARITY THERAPEUTICS INC (ALLR) has a support level at 0.8 and a resistance level at 1.01. Check the full technical report for a detailed analysis of ALLR support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ALLR does not pay a dividend.
ALLARITY THERAPEUTICS INC (ALLR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-123690).
The outstanding short interest for ALLARITY THERAPEUTICS INC (ALLR) is 8.2% of its float. Check the ownership tab for more information on the ALLR short interest.
ChartMill assigns a fundamental rating of 2 / 10 to ALLR. ALLR scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months ALLR reported a non-GAAP Earnings per Share(EPS) of -123690. The EPS increased by 97.83% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -117.8% | ||
ROE | -185.17% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 43% to ALLR. The Buy consensus is the average rating of analysts ratings from 6 analysts.